Cardiometabolic Diseases Global Market Report 2024

The cardiometabolic diseases market size has grown steadily in recent years. It will grow from $106.3 billion in 2023 to $110.9 billion in 2024 at a compound annual growth rate (CAGR) of 4.3%. The historical growth in cardiometabolic diseases can be attributed to factors such as sedentary lifestyles, urbanization leading to changes in lifestyle, industrialization promoting processed foods, genetic predispositions, and environmental factors.

The cardiometabolic diseases market size is expected to see steady growth in the next few years. It will grow to $128.98 billion in 2028 at a compound annual growth rate (CAGR) of 3.8%. The forecasted growth in cardiometabolic diseases is expected to be driven by factors such as the obesity epidemic, the aging population, ongoing developments in healthcare infrastructure, advancements in genomic and precision medicine, and the impact of chronic stress on mental health. Key trends in the forecast period include an emphasis on health education and awareness, the implementation of corporate wellness programs, community health initiatives, a focus on preventive healthcare, and the adoption of integrated care approaches.

A surge in obesity rates is anticipated to be a significant driver propelling the growth of the cardiometabolic disease market. Obesity, characterized by an excess accumulation of body fat leading to increased body weight, significantly impacts the prevalence of cardiovascular risk factors such as dyslipidemia, type 2 diabetes, hypertension, and sleep disorders. As reported by the World Health Organization (WHO) in March 2022, globally, more than 1 billion individuals grapple with obesity, including 340 million teenagers, 650 million adults, and 39 million children annually. By 2025, the WHO predicts that 167 million adults and children will face health complications stemming from being overweight or obese. This high prevalence of obesity is a pivotal driver fostering the growth of the cardiometabolic diseases market.

The expansion of the aging population is playing a crucial role in bolstering the cardiometabolic diseases market. A growing aging population refers to a demographic shift where the proportion of elderly individuals, typically aged 65 and above, rises in relation to the overall population. Cardiometabolic diseases, encompassing cardiovascular diseases and metabolic disorders such as diabetes, exhibit higher prevalence among older age groups. Aging is accompanied by physiological changes, including metabolic alterations and increased susceptibility to cardiovascular ailments, contributing to the elevated incidence of cardiometabolic diseases in older demographics. For example, data released by the World Health Organization (WHO) in October 2022 indicated a projection of the population aged 60 or above surging from 1 billion in 2020 to 1.4 billion in 2030. Consequently, the burgeoning aging population stands as a significant force driving the cardiometabolic diseases market.

The rising trend within the cardiometabolic diseases market centers on the adoption of cutting-edge technologies. Companies engaged in this sector are actively pursuing innovative technologies to maintain their competitive edge. For example, in February 2023, Eko Health Inc., a US-based innovator in digital health technologies for heart and lung disease detection, introduced the Sensora cardiac disease detection platform. This platform integrates artificial intelligence (AI) capable of accurately detecting structural murmurs, a key indicator of valvular heart disease (VHD). Additionally, the platform incorporates care pathway analytics software, offering valuable metrics and insights into patients' healthcare journeys. The digital stethoscope component of this technology captures and analyzes heartbeats and electrical impulses, enhancing diagnostic capabilities.

Prominent entities operating in the cardiometabolic diseases market are dedicated to developing wearable devices designed for continuous monitoring of patients with cardiometabolic conditions. Continuous monitoring facilitates early detection of cardiometabolic disease symptoms, enabling proactive intervention in the early stages of the disease. For instance, in September 2023, Kilele Health, a healthcare company based in Kenya, unveiled wearable remote continuous patient monitoring specifically tailored for cardiometabolic diseases. This innovation empowers both healthcare professionals and patients by delivering accurate real-time data, thereby enabling timely interventions and improved disease management strategies.

In December 2021, Novo Nordisk, a Denmark-based healthcare company, successfully acquired Dicerna Pharmaceuticals for a significant sum of $3.3 billion. This strategic acquisition aligns with Novo Nordisk's broader strategy, focusing on the development and application of diverse technology platforms across various therapeutic areas. Dicerna Pharmaceuticals, based in the United States, is a prominent biopharmaceutical company.

Major companies operating in the cardiometabolic diseases market report are Pfizer Inc., Johnson & Johnson, F. Hoffmann-La Roche AG, Merck & Co Inc., AbbVie Inc., Bayer AG, Novartis AG, Sanofi SA, Kowa Company Ltd., Thermo Fisher Scientific, Abbott Laboratories, Takeda Pharmaceutical Company, Eli Lilly and Company, Novo Nordisk A/S, Siemens Healthineers, Boehringer Ingelheim International GmbH, Becton, Dickinson and Company, Stryker Corporation, AstraZeneca PLC, Viatris Inc., Biocrates Life Sciences AG, Boston Scientific, Astellas Pharma Inc., Terumo Corporation, Agilent Technologies, Edwards Lifesciences, Bruker Corporation, Alnylam Pharmaceuticals Inc., Arrowhead Pharmaceuticals Inc., Cardax Inc.


North America was the largest region in the cardiometabolic diseases market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the cardiometabolic diseases market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the cardiometabolic diseases market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The primary types of cardiometabolic diseases include chronic or congestive heart failure, hypertension, type 2 diabetes, and obesity. Congestive heart failure is a chronic condition where the heart's ability to pump blood efficiently is compromised. Treatment modalities encompass ACE inhibitors, diuretics, glucophage, liposuction, and various therapeutic approaches. Medications are available in tablet and injection forms, administered through various routes such as oral and intravenous. These solutions cater to diverse end-users, including clinics and hospitals.

The cardiometabolic diseases market research report is one of a series of new reports that provides cardiometabolic diseases market statistics, including cardiometabolic diseases industry global market size, regional shares, competitors with a cardiometabolic diseases market share, detailed cardiometabolic diseases market segments, market trends, and opportunities, and any further data you may need to thrive in the cardiometabolic diseases industry. This cardiometabolic diseases market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The cardiometabolic diseases market consists of revenues earned by entities by providing services such as non-invasive CAD testing, cardio-preventive care, behavioral counseling, and clinical assessment. The market value includes the value of related goods sold by the service provider or included within the service offering. The cardiometabolic diseases market also includes sales of medications, blood glucose monitoring devices, blood pressure monitors, cholesterol testing kits, and weight management products used to provide cardiometabolic diseases services. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.